Pegcetacoplan was approved by the FDA to treat geographic atrophy (GA), providing a treatment option for patients who previously had none, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.
Pegcetacoplan was approved by the FDA to treat geographic atrophy (GA), providing a treatment option for patients who previously had none, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.
The drug was approved by the FDA on February 17 ahead of the decision date, which was February 28. Lad presented the 2-year results of pegcetacoplan from the DERBY and OAKS trials earlier in February at the Angiogenesis, Exudation, and Degeneration 2023 meeting. She explained then that the drug’s effect to slow disease progression increases over time as patients take the drug for longer.
Transcript
Geographic atrophy is a huge clinical unmet need that has had no answers in the past, we've had no previously approved options. Speaking to the experience of a patient living with geographic atrophy, I can tell you, it's really debilitating when it becomes severe. I had a patient the other day, they told me, “I would walk to the end of the world to get any information about trials or any way to get help.” Not even a treatment, but anything in the pipeline. So, for this type of patient—and there are many—any approved treatment is a dream come true.
Now that we have this approval, it's the beginning of a treatment of a major disease. We didn't have this option the past, and we're very grateful. It's a really exciting first treatment for geographic atrophy, a really exciting time for drying [age-related macular degeneration] as a space. And I'm looking forward to beginning the treatment of GA patients in the future.
This will give the patient's renewed hope that they'll be able to do everything they enjoy doing, see their family members, and live a fulfilling life.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More